ArticleThe Saudi dental journal2026
Comparative efficacy of locally delivered 1.2% rosuvastatin and 1.2% simvastatin gel as an adjunct to non-surgical periodontal therapy in chronic periodontitis: a clinical and microbiological assay.
Article in The Saudi dental journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To evaluate and compare the clinical and microbiological efficacy of locally administered 1.2% Rosuvastatin (RSV) gel and 1.2% Simvastatin (SMV) gel as an adjunct to scaling and root planing (SRP) in the treatment of patients with chronic periodontitis. In this exploratory comparative study, 60 qualifying periodontal pockets (probing pocket depth [PPD] of 5-7 mm) from patients aged 25-55 years were randomized into three groups ($n = 20$ pockets per group): Group I received SRP + local delivery of 1.2% RSV gel; Group II received SRP + local delivery of 1.2% SMV gel; and Group III (control) received SRP + placebo gel. Clinical parameters-Plaque Index (PI), Modified Gingival Index (MGI), Sulcus Bleeding Index (SBI), PPD, and Clinical Attachment Loss (CAL)-were evaluated at baseline, 6 weeks, and 3 months. Microbiological assessment of Porphyromonas gingivalis (Pg) and Aggregatibacter actinomycetemcomitans (Aa) was performed using Polymerase Chain Reaction (PCR) at baseline and 6 weeks. All 60 sites completed the study with no dropouts or adverse reactions. At 6 weeks and 3 months, both statin groups (Groups I and II) demonstrated statistically significant reductions in MGI, SBI, PPD, and CAL compared to the placebo group ($P < 0.05$). The statin groups also showed significantly lower levels of Aa and Pg at 6 weeks. Comparison between the two statins revealed that the SMV group achieved greater reductions in clinical indices (MGI, SBI, PPD, CAL) and bacterial counts (Aa and Pg) than the RSV group; however, this difference was not statistically significant (P < 0.05). No significant differences in PI scores were found between any of the groups at any interval (P < 0.05). The local delivery of both 1.2% simvastatin gel and 1.2% rosuvastatin gel as adjuncts to non-surgical periodontal therapy significantly improved clinical and microbiological outcomes in chronic periodontitis. While simvastatin demonstrated slightly greater absolute improvements than rosuvastatin, the overall therapeutic difference between the two statins was not statistically significant.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.